Chondroitin sulfate for the treatment of hip and knee osteoarthritis: Current status and future trends

Life Sciences

Volumn 85, Issue 13-14, 2009, Pages 477-483

  Kubo, Mitsuhiko ^a   Ando, Kosei ^a   Mimura, Tomohiro ^a   Matsusue, Yoshitaka ^a   Mori, Kanji ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Articular cartilage; Chondroitin sulfate; Osteoarthritis; Treatment

Indexed keywords

ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CELECOXIB; CHONDROITIN SULFATE; CYTOKINE INHIBITOR; GLUCOCORTICOID; GLUCOSAMINE; HERBACEOUS AGENT; MATRIX METALLOPROTEINASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CARTILAGE CELL; CARTILAGE DEGENERATION; CHONDROPROTECTION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EXTRACELLULAR MATRIX; GASTROINTESTINAL DISEASE; HIP OSTEOARTHRITIS; HUMAN; KIDNEY DISEASE; KNEE OSTEOARTHRITIS; MONOTHERAPY; NONHUMAN; ORAL MUCOSAL DISEASE; REVIEW; SKIN DISEASE; STRUCTURE ANALYSIS; SURGICAL TECHNIQUE; TREATMENT DURATION; TREND STUDY; ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHONDROCYTES; CHONDROITIN SULFATES; HUMANS; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE;

EID: 70249116001     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2009.08.005     Document Type: Review

References (71)

1. Agarwal S., Deschner J., Lomg P., Verma A., Hofman C., Evans C.H., and Piesco N. Role of NF-kappaB transcription factors in anti-inflammatory and proinflammatory actions of mechanical signals. Arthritis and Rheumatism 50 11 (2004) 3541-3548
2. Aigner T., Soeder S., and Haag J. IL-1beta and BMPs-interactive players of cartilage matrix degradation and regeneration. European Cell and Materials 12 26 (2006) 49-56
3. Andermann G., and Dietz M. The influence of the rout of administration on the bioavailability of an endogenous macromolecule: chondroitin sulfate (CSA). European Journal of Drug Metabolism and Pharmacokinetics 7 1 (1982) 11-16
4. Baici A., and Bradamante P. Interaction between human leukocyte elastase and chondroitin sulfate. Chemico-Biological Interactions 51 1 (1984) 1
5. Baici A., Hörler D., Moser B., Hofer H.O., Fehr K., and Wagenhäuser F.J. Analysis of glycosaminoglycans in human serum after oral administration of chondroitin sulfate. Rheumatology International 12 3 (1992) 81-88
6. Bassleer C., Henrotin Y., and Franchimont P. In-vitro evaluation of drugs proposed as chondroprotective agents. International Journal of Tissue Reactions 14 5 (1992) 231-241
7. Bassleer C.T., Combal J.P., Bougaret S., and Malaise M. Effect of chondroitin sulfate and interleukin-1β on human articular chondrocuytes cultivated in clusters. Osteoarthritis and Cartilage 6 3 (1998) 196-204
8. Bellamy N. Osteoarthritis clinical trials: candidate variables and clinimetric properties. Journal of Rheumatology 24 4 (1997) 768-778
9. Bjordal J.M., Klovning A., Ljunggren A.E., and Slørdal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomized placebo-controlled trials. European Journal of Pain 11 2 (2007) 125-138
10. Bourgeois P., Chales G., Dehais J., Delcambre B., Kuntz J.L., and Rozenberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis and Cartilage 6 Supple A (1998) 25-30
11. Buckwalter J.A., Saltzman C., and Brown T. The impact of osteoarthritis. Clinical Orthopedics and Related Research 427S (2004) S6-S15
12. Bucsi L., and Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis and Cartilage 6(Supple A) (1998) 31-36
13. Center for Disease Control and Prevention. Prevalence of self-reported arthritis or chronic joint symptoms among adults-United States, 2001. Morbidity and Mortality Weekly Report 51 42 (2002) 948-950
14. Center for Disease Control and Prevention. Public health and aging: projected prevalence of self-reported arthritis or chronic joint symptoms among persons aged > 65 years: United States, 2005-2030. Morbidity and Mortality Weekly Report 52 21 (2003) 489-491
15. Chalmers T.C., Smith Jr. H., Blackburr B., Silverman B., Schroeder B., Reitman D., and Ambroz A. A method for assessing the quality of a randomized control trial. Controlled Clinical Trials 2 1 (1981) 31-49
16. Clegg D.O., Reda D.J., Harris C.L., Klein M.A., O'Dell J.R., Hooper M.M., Bradley J.D., Bingham III C.O., Weisman M.H., Jackson C.G., Lane N.E., Cush J.J., Moreland L.W., Schumacher Jr. H.R., Oddis C.V., Wolfe F., Molitor J.A., Yocum D.E., Schnitzer T.J., Furst D.E., Sawitzke A.D., Shi H., Brandt K.D., Moskowitz R.W., and Williams H.J. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine 354 8 (2006) 795-808
17. Conte A., Palmieri L., Segnini D., and Ronca G. Metabolic fate of partially depolimerized chondroitin sulfate administered to the rat. Drugs Under Experimental and Clinical Research 17 1 (1991) 27-33
18. Conte A., de Bernardi M., Palmieri L., Lualdi P., Mautone G., and Ronca G. Metabolic fate of exogenous chondroitin sulfate in man. Arzneimittel-Forschung 41 7 (1991) 768-772
19. Conte A., Volpi N., and Palmieri L. Biochemical and pharmacokinetic aspect of oral treatment with chondroitin sulfate. Arzneimittel-Forschung 45 8 (1995) 918-925
20. Dohlman C.H. The fate of the sulfate group of chondroitin sulfate after administration to rats. Acta Physiologica Scandinavica 37 2-3 (1956) 220-234
21. 35S in the rat. Journal of Biological Chemistry 223 1 (1956) 239-249
22. Fajardo M., and Di Cesare P.E. Disease-modifying therapies for osteoarthritis: current status. Drugs and Aging 22 2 (2005) 141-161
23. Hashimoto S., Ochs R.L., Komiya S., and Lotz M. Linkage of chondrocyte apoptosis and cartilage degradation in human osteoarthritis. Arthritis and Rheumatism 41 9 (1998) 1632-1638
24. Hung D. Effect of extracellular chondroitin sulfate on cultured chondrocytes. Journal of Cell Biology 62 3 (1974) 881-886
25. Johnson K.A., Hulse D.A., Hart R.C., Kochevar D., and Chu Q. Effects of an orally administered mixture of chondroitin sulfate, glucosamine hydrochloride and manganese ascorbate on synovial fluid chondroitin sulfate 3B3 and 7D7 epitope in a canine cruciate ligament transaction model of osteoarthritis. Osteoarthritis and Cartilage 9 1 (2001) 14-21
26. Jomphe C., Gabriac M., Hale T.M., Héroux L., Trudeau L.E., Deblois D., Montell E., Vergés J., and du Souich P. Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-κB in interleukin-1β-stimulated chondrocytes. Basic & Clinical Pharmacology & Toxicology 102 1 (2008) 59-65
27. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W., Dieppe P., Gunther K., Hauselmann H., Herrero-Beaumont G., Kaklamanis P., Lohmander S., Leeb B., Lequesne M., Mazieres B., Martin-Mola E., Pavelka K., Pendleton A., Punzi L., Serni U., Swoboda B., Verbruggen G., and Zimmerman-Gorska I. Dougados M; Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis. Annals of the Rheumatic Diseases 62 12 (2003) 1145-1155
28. Konador A., and Kawiak J. Distribution of radioactivity in the mouse organism after administration of 35S-chondroitin sulfate. Frontiers of Biology 24 2 (1976) 177-190
29. Konador A., and Kawiak J. Changes in chondroitin sulfate concentration in rabbit blood plasma depending on the method of its administration. Archivum Immunologiae et Therapiae Experimentalis 25 6 (1977) 895-903
30. Kubo M., Takase T., Matsusue Y., Rauvala H., and Imai S. Articular cartilage degeneration and de-differentiation of chondrocytes by the systemic administration of retinyl acetate-ectopic production of osteoblast stimulating factor-1 by chondrocytes in mice. Osteoarthritis and Cartilage 10 12 (2002) 968-976
31. Kubo M., Matsusue Y., and Imai S. Basic science of the articular cartilage and clinical application to the cartilage regeneration. In: Pandalai S.G. (Ed). Recent Research Development in Cell Biology vol 1 (2003), Transworld Research Network, Kerala 155-175
32. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointestinal Endoscopy Clinics of North America 6 3 (1996) 489-504
33. Lanza F.L., Chan F.K.L., Quigley E.M.M., and and the Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. American Journal Gastroenterology 104 3 (2009) 728-738
34. Lawrence R.C., Felson D.T., Helmick C.G., Arnold L.M., Choi H., Deyo R.A., Gabriel S., Hirsch R., Hochberg M.C., Hunder G.G., Jordan J.M., Katz J.N., and Kremers H.M. Wolfe F; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis and Rheumatism 58 1 (2008) 26-35
35. Leeb B.F., Schweitzer H., Montag K., and Smolen J.S. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. Journal of Rheumatology 27 1 (2000) 205-211
36. Legendre F., Bauge C., Roche R., Saurel A.S., and Pujol J.P. Chodroitin sulfate modulation of matrix and inflammatory gene expression in IL-1β-stimulated chondrocytes - study in hypoxic alginate bead cultures. Osteoarthritis and Cartilage 16 1 (2008) 105-114
37. Lequesne M.G., Mery C., Samson M., and Gerard P. Index of severity for osteoarthritis of the hip and knee. Validation-value in comparison with other assessment test. Scandinavian Journal of Rheumatology Suppl.65 (1987) 85-89
38. Lequesne M., Brandt K., Bellamy N., Moskowitz R., Menkes C.J., Pelletier J.P., and Altman R. Guidelines for testing slow acting drugs in osteoarthritis. Journal of Rheumatology 41(Suppl) (1994) 65-71
39. Lin Z., Fitzgerald J.B., Xu J., Willers C., Wood D., Grodzinsky A.J., and Zheng M.H. Gene expression profiles of human chondrocytes during passaged monolayer cultivation. Journal of Orthopedic Research 26 9 (2008) 1230-1237
40. Lippiello L. Glucosamine and chondroitin sulfate: biological response modifiers of chondrocytes under stimulated conditions of joint stress. Osteoarthritis and Cartilage 11 5 (2003) 335-342
41. Lippiello L., Woodward J., Karpman R., and Hammad T.A. In vivo chondroprotection and metabolic synergy of glycosamine and chondroitin sulfate. Clinical Orthopedics and Related Research 381 (2000) 229-240
42. Mazieres B., Combe B., Van A.P., Tondut J., and Grynfeltt M. Chondroitin sulfate in osteoarthritis of the knee: prospective, double blind, placebo controlled multicenter clinical study. Journal of Rheumatology 28 1 (2001) 173-181
43. McAlindon T., LaValley M.P., Gulin J.P., and Felson D.T. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. Journal of the American Medical Association 283 11 (2000) 1469-1475
44. Meachim G., Ghadially F.N., and Collins D.H. Regressive changes in the superficial layer of human articular cartilage. Annals of the Rheumatic Diseases 24 (1965) 23-30
45. Michel B.A., Stucki G., Frey D., De Vathaire F., Vignon E., Bruehlmann P., and Uebelhart D. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis and Rheumatism 52 3 (2005) 779-786
46. Monfort J., Martel-Pelletier J., and Pelletier J.P. Chondroitin sulfate for symptomatic osteoarthritis: critical appraisal of meta-analyses. Current Medical Research and Opinion 24 5 (2008) 1303-1308
47. Morreale P., Manopulo R., Galati M., Boccanera L., Saponati G., and Bocchi L. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Journal of Rheumatology 23 8 (1996) 1385-1391
48. Murata K., and Yokoyama Y. Enzymatic analysis with chondrosulfatases of constituent disaccharides of sulfated chondroitin sulfate and dermatan sulfate isomers by high-performance liquid chromatography. Analytical Biochemistry 149 1 (1985) 261-268
49. Nishimoto S., Takagi M., Wakitani S., Nihira T., and Yoshida T. Effect of chondroitin sulfate and hyaluronic acid on gene expression in a three-dimensional culture of chondrocytes. Journal of Bioscience and Bioengineering 100 1 (2005) 123-126
50. Palmieri L., Conte A., Giovannini L., Lualdi P., and Ronca G. Metabolic fate of exogenous chondroitin sulfate in the experimental animal. Arzneimittel-Forschung 40 3 (1990) 319-323
51. Qvist P., Bay-Jensen A.-C., Christiansen C., Dam E.B., Pastoureau P., and Karsdal M.A. The disease modifying osteoarthritis drug (DMOAD): is it in the horizon?. Pharmacological Research 58 (2008) 1-7
52. Reichenbach S., Sterchi R., Scherer M., Trelle S., Bürgi E., Bürgi U., Dieppe P.A., and Jüni P. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine 146 8 (2007) 580-590
53. Richy F., Bruyere O., Ethgen O., Cucherat M., Henrotin Y., and Reginster J.Y. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Archives of Internal Medicine 163 13 (2003) 1514-1522
54. Roman-Blas J.A., and Jimenez S.A. NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis and Cartilage 14 9 (2006) 839-848
55. Ronca G., and Conte A. Metabolic fate of partially depolymerized shark chondroitin sulfate in man. International Journal of Clinical Pharmacology Research 13(Suppl) (1993) 27-34
56. Ronca F., Palmieri L., Panicucci P., and Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarhritis and Cartilage 6 (Supple A) (1998) 14-21
57. Schwartz N.B., and Dorfman A. Stimulation of chondroitin sulfate proteoglycan production by chondrocytes in monolayer. Connective Tissue Research 3 2 (1975) 115-122
58. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N.M., Stenson W.F., Burr A.M., Zhao W.W., Kent J.D., Lefkowith J.B., Verburg K.M., and Geis G.S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. Journal of the American Medical Association 284 10 (2000) 1247-1255
59. Steinmeyer J., and Konttinen Y.T. Oral treatment for degenerative joint disease-presence and future. Advanced Drug Delivery Reviews 58 2 (2006) 168-211
60. Stürmer T., Erb A., Keller F., Günther K.P., and Brenner H. Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: the importance of half-life and other medications. American Journal of Medicine 111 7 (2001) 521-527
61. Takahashi T., Ogawara T., Asawa Y., Mori Y., Uchinuma E., Takato T., and Hoshi K. Three-dimensional microenvironment retain chondrocyte phenotypes during proliferation culture. Tissue Engineering 13 7 (2007) 1583-1592
62. Uebelhart D. Clinical review of chondroitin sulfate in osteoarthritis. Osteoarthritis and Cartilage 16 Suppl 3 (2008) S19-S21
63. Uebelhart D., Thonar E.J., Zhang J., and Williams J.M. Protective effect of exogenous chondroitin 4,6-sulfate in the acute degeneration of articular cartilage in the rabbit. Osteoarthritis and Cartilage 6(Suppl A) (1998) 6-13
64. Uebelhart D., Malaise M., Marcolongo R., de Vathaire F., Piperno M., Mailleux E., Fioravanti A., Matoso L., and Vignon E. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis and Cartilage 12 4 (2004) 269-276
65. Verbruggen G., and Veys E.M. Influence of glycosaminoglycans upon proteoglycans metabolism of the synovial lining cells. Acta Rhumatologica Belgica 1 1-2 (1977) 75-92
66. Volpi N. Oral bioavailability of chondroitin sulfate (Condrosulf) and its constituents in healthy male volunteers. Osteoarthritis and Cartilage 10 10 (2002) 768-777
67. Volpi N. Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers. Osteoarthritis and Cartilage 11 6 (2003) 433-441
68. Volpi N., Bolognani L., Conte A., and Petrini M. Effects of chondroitin sulfates with different structures on leukemia cells: U-937 cell proliferation and differentiation. Leukemia Research 17 9 (1993) 789-798
69. Winkelmayer W.C., Waikar S.S., Mogun H., and Solomon D.H. Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. American Journal of Medicine 121 12 (2008) 1092-1098
70. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., Bierma-Zeinstra S., Brandt K.D., Croft P., Doherty M., Dougados M., Hochberg M., Hunter D.J., Kwoh K., Lohmander L.S., and Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part I: Critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis and Cartilage 15 9 (2007) 981-1000
71. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., Bierma-Zeinstra S., Brandt K.D., Croft P., Doherty M., Dougados M., Hochberg M., Hunter D.J., Kwoh K., Lohmander L.S., and Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage 16 2 (2008) 137-162